Protego Biopharma raised $130 million in an oversubscribed Series B to advance PROT-001, an oral small-molecule kinetic stabilizer of lambda immunoglobulin light chains, into a pivotal trial expected in the second half of 2026. PROT-001 is designed to stabilize misfolded light chains and prevent amyloid deposition, addressing AL amyloidosis at the protein-folding level rather than by eliminating plasma cell clones. CEO Brent Warner said the company expects PROT-001 to be tested alongside standard-of-care regimens and that the small-molecule chaperone approach could translate to other protein misfolding diseases. The company cited tafamidis as precedent for kinetic stabilizers but positioned PROT-001 as distinct for light-chain amyloidosis. The financing expands Protego’s runway for pivotal work and underscores investor interest in oral, disease-modifying approaches for systemic amyloid disorders.